<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow aspirates and biopsies of 20 patients with <z:mp ids='MP_0002018'>malignant tumors</z:mp> (n = 6), <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> due to chemotherapy (n = 4), <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (n = 5) and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (n = 5) were analysed before and after treatment with recombinant human interleukin-3 </plain></SENT>
<SENT sid="1" pm="."><plain>rhIL-3 led to increased overall bone marrow cellularity with trilinear stimulation of hematopoietic cells </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> patients marked <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> and, in some, <z:mp ids='MP_0003045'>fibrosis</z:mp> was observed </plain></SENT>
<SENT sid="3" pm="."><plain>These results show that rhIL-3 stimulates the proliferation and differentiation of pluripotent hematopoietic progenitor cells and may contribute to the treatment of <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> </plain></SENT>
</text></document>